Emilia Bulaevsky Zychlinsky
Operationeel Directeur bij Exai Bio, Inc.
Actieve functies van Emilia Bulaevsky Zychlinsky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Exai Bio, Inc.
 Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Operationeel Directeur | 02-02-2023 | - |
Loopbaan van Emilia Bulaevsky Zychlinsky
Eerdere bekende functies van Emilia Bulaevsky Zychlinsky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| DIADEXUS, INC. | Hoofd Techniek/Wetenschap/O&O | 10-01-2011 | 01-04-2016 |
Minaris Medical America, Inc.
 Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Hoofd Techniek/Wetenschap/O&O | - | - |
| Algemeen Adviseur | - | - | |
| STANDARD BIOTOOLS INC. | Algemeen Adviseur | 01-04-2016 | - |
Opleiding van Emilia Bulaevsky Zychlinsky
| Stanford University | Doctorate Degree |
| Instituto Politecnico Nacional | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Mexico | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| General Counsel | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
| Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| STANDARD BIOTOOLS INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Minaris Medical America, Inc.
Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |
